Larimar Therapeutics Management
Management criteria checks 2/4
Larimar Therapeutics' CEO is Carole Ben-Maimon, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is $3.14M, comprised of 17.8% salary and 82.2% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €668.91K. The average tenure of the management team and the board of directors is 4.3 years and 4.3 years respectively.
Key information
Carole Ben-Maimon
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 17.8% |
| CEO tenure | 4.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$65m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$3m | US$560k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$2m | US$528k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$510k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$49m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$5m | US$268k | -US$42m |
Compensation vs Market: Carole's total compensation ($USD3.14M) is above average for companies of similar size in the German market ($USD1.03M).
Compensation vs Earnings: Carole's compensation has increased whilst the company is unprofitable.
CEO
Carole Ben-Maimon (65 yo)
4.5yrs
Tenure
US$3,137,432
Compensation
Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.5yrs | US$3.14m | 0.18% € 668.9k | |
| Secretary & CFO | 4.5yrs | US$1.42m | 0.087% € 329.8k | |
| Chief Development Officer | 1.8yrs | US$1.43m | 0.0078% € 29.6k | |
| Vice President of Finance & Administration | 1.3yrs | no data | no data | |
| Vice President of Legal & Compliance | 7.9yrs | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data | |
| VP & Controller | 4.3yrs | no data | no data |
4.3yrs
Average Tenure
64yo
Average Age
Experienced Management: ZA71's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.5yrs | US$3.14m | 0.18% € 668.9k | |
| Independent Director | 4.5yrs | US$79.96k | no data | |
| Independent Director | 1.1yrs | US$56.43k | 0% € 0 | |
| Independent Director | 10.4yrs | US$86.21k | 0.0031% € 11.8k | |
| Independent Director | 4.5yrs | US$77.77k | 0.89% € 3.3m | |
| Independent Chairman of the Board | 4.5yrs | US$114.96k | 0.0043% € 16.3k | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data |
4.3yrs
Average Tenure
57.5yo
Average Age
Experienced Board: ZA71's board of directors are considered experienced (4.3 years average tenure).